(Wynnewood, Pa.) – Lankenau Institute for Medical Research, the biomedical research center for Main Line Health, received a $3.1 million, five-year grant award from the National Cancer Institute (NCI) to conduct clinical trials of new oncology drugs and perform additional research to improve patient care.
This award for an NCI Community Oncology Research Program (NCORP) supports all NCI-sponsored clinical trials, which is conducted by Main Line Health oncologists, relates to cancer prevention, screening, treatment and post-treatment management. NCORP also supports research into cancer care delivery, which focuses on improving health and quality of life outcomes, identifying and addressing any disparities of care among individual patients, and gaining a more integrated understanding of all the costs involved in effective health management.
Main Line Health is one of only 34 health care organizations in the U.S. to receive an NCORP award from NCI, testifying to the national strengths of the Main Line Health hospitals in delivering and continuously improving cancer care. NCORP supports oncology research at all Main Line Health hospitals, including Lankenau Medical Center, Bryn Mawr, Paoli, and Riddle hospitals.
The Principal Investigator for the Main Line Health NCORP award is Albert DeNittis, MD, Chief of Radiation Oncology at Lankenau Medical Center, with Associate Principal Investigator John Devlin, MD, Bryn Mawr Hospital; site investigators Michael Dabrow, DO, at Paoli Hospital; and Rashmi Sanjay, MD, at Riddle Hospital.
“Having the NCORP available at all four acute care hospitals in the system expands the access our patients have to innovative treatment care options and highlights another way we strive to provide a superior patient experience to each Main Line Health patient,” said Diana Blade, Administrator of Cancer Clinical Trials at Lankenau Institute for Medical Research. “Our relationship with the NCI allows us to contribute in a meaningful way to cancer research and treatments that lead to medical breakthroughs.”
Founded in 1985, Main Line Health is a not-for-profit health system serving portions of Philadelphia and its western suburbs. Main Line Health’s commitment—to deliver advanced medicine to treat and cure disease while also playing an important role in prevention and disease management as well as training physicians and other health care providers—reflects our intent to keep our community and ourselves well ahead. A team of more than 10,000 employees and 2,000 physicians care for patients throughout the Main Line Health system.
At Main Line Health’s core are four of the region’s most respected acute care hospitals—Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital—as well as one of the nation’s recognized facilities for rehabilitative medicine, Bryn Mawr Rehabilitation Hospital.
The Main Line Health system also includes Mirmont Treatment Center for drug and alcohol recovery; Main Line Health HomeCare & Hospice, which includes skilled home health care, hospice and home infusion services; Main Line Health Centers, primary and specialty care, lab and radiology, and other outpatient services located in Broomall, Collegeville, Concordville, Exton and Newtown Square; Lankenau Institute for Medical Research, a biomedical research organization; and Main Line HealthCare, one of the region’s largest multispecialty physician networks.
Main Line Health is the recipient of numerous awards for quality care and service, including System Magnet® designation, the nation’s highest distinction for nursing excellence, the Mid-Atlantic Alliance for Performance Excellence (MAAPE) Excellence Award, and recognition as among the nation’s best employers by Forbes magazine. Main Line Health is committed to creating an environment of diversity, respect and inclusion and has proudly embraced the American Hospital Association’s #123forEquity Pledge to Act to eliminate disparities in care. We are dedicated to advancing patient-centered care, education and research to help our community stay healthy.
Lankenau Institute for Medical Research (LIMR) is a nonprofit biomedical research institute located on the campus of Lankenau Medical Center and is part of Main Line Health. Founded in 1927, LIMR’s mission is to improve human health and well-being. Faculty and staff are devoted to advancing innovative new approaches to formidable medical challenges, including cancer, cardiovascular disease, gastrointestinal disorders and autoimmune diseases, such as diabetes and arthritis. LIMR’s principal investigators conduct basic, preclinical and translational research, using their findings to explore ways to improve disease detection, diagnosis, treatment and prevention. They are committed to extending the boundaries of human health through technology transfer and training of the next generation of scientists and physicians.